What Happened
A pharmacist in Franklin, Kentucky, and his wife were sentenced to federal prison after conspiring to divert oxycodone and hydrocodone from his pharmacy and fraudulently bill Medicaid and private insurers.
From May 2, 2020 to January 17, 2023, the pharmacist and his wife diverted oxycodone and hydrocodone from the pharmacy, with the wife selling or trading the controlled substances for cocaine, methamphetamine, and marijuana. They also fraudulently billed Kentucky Medicaid for prescriptions that had not been ordered by a physician or nurse practitioner. The pharmacist separately billed insurance companies for brand-name Adderall when generic Adderall had actually been dispensed, billed for medication never dispensed at all, used another medical professional's name and National Provider Identifier to issue prescriptions without that provider's knowledge, and falsely reported a pharmacy robbery to the DEA when no drugs had actually been stolen.
The pharmacist was sentenced to three years in federal prison, followed by three years of supervised release, on one count of conspiracy to commit theft of medical products, one count of conspiracy to unlawfully distribute controlled substances, twelve counts of health care fraud, one count of aggravated identity theft, and one count of making a false statement. He was ordered to pay $17,518.19 in restitution. His wife was sentenced to two years in prison, followed by three years of supervised release, on related conspiracy and health care fraud counts, and ordered to pay $5,730.43 in restitution.
What Went Wrong
A pharmacy owner used his position to divert opioids, falsify records across multiple insurers, and fabricate a robbery report to cover inventory shortages. Key failure points:
- Owner-level access went unchecked. As the pharmacist-in-charge, he could conceal diversion behind billing and inventory records he controlled directly, with no independent oversight of his own transactions.
- A false robbery report delayed detection. By reporting a fabricated robbery to the DEA, the pharmacist created a false explanation for missing inventory that could have delayed scrutiny of the actual diversion.
- Billing fraud crossed multiple payers. Fraudulent claims to Medicaid and private insurers, and misuse of another provider's identity, suggest no cross-payer reconciliation caught the pattern of inconsistent billing.
- A close relationship enabled resale. Diverted opioids were funneled directly into resale and trade for other drugs by a family member with routine access to the pharmacy, rather than being confined to personal use.
How It Could Have Been Prevented
- Require independent, periodic audits of pharmacy owners' and pharmacists-in-charge's own controlled-substance transactions, not just front-line staff.
- Verify DEA theft or loss reports against physical inventory counts and dispensing records before accepting them as an explanation for shortages.
- Cross-check billing submitted to Medicaid and private insurers against actual dispensing records and prescriber identities on a routine basis.
- Restrict family member or personal-associate access to areas of the pharmacy where controlled substances are stored or handled.
- Report and investigate any prescriptions issued using a provider identity inconsistent with the actual prescriber on record.
Related Guidance
- Pharmacy Self-Assessment Checklist — Pharmacy-specific self-assessment covering ownership and staff controls.
- Controlled Substance Inventory Guide — Reconciliation, cycle counts, and biennial inventory requirements.
- 15 Red Flags of Drug Diversion — Behavioral and recordkeeping indicators of diversion, including by pharmacy owners.
- DEA Inspection Prep — What to expect and how to prepare for a DEA compliance inspection.
- Investigation Playbook — How to run an internal diversion investigation when staff or product integrity is questioned.